Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention
TUCSON, Ariz. , May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023
Toggle Summary HTG Highlights the Advantages of Its Drug Discovery Engine
TUCSON, Ariz. , May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business.
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights
TUCSON, Ariz. , May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights.
Toggle Summary HTG Provides Update on Drug Discovery Partnering Initiative
TUCSON, Ariz. , April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit.
Toggle Summary HTG Announces Key First Quarter Milestone Achievements for Drug Discovery
TUCSON, Ariz. , April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023.

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Quarterly report which provides a continuing view of a company's financial position